Clinical Trial Update: Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating tremelimumab with durvalumab, high-dose chemotherapy, and autologous stem cell transplant in multiple myeloma was terminated; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Autologous Stem Cell Transplant
• Durvalumab (durvalumab)
• High-dose chemotherapy (high-dose chemotherapy)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2019-03-26